Gastrointestinal Stromal Tumor
📧 Sign up to get email alerts when something new happens for Gastrointestinal Stromal Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-05-28Clinical Trial Update: Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
Expanded access to Everolimus for an individual patient with Gastrointestinal Stromal Tumor has ended and is no longer available.
-
EMA withdrawal · 2013-11-22EMA Refused: Masican (masitinib) — AB Science
EMA refused Masican (masitinib) for gastrointestinal stromal tumors; the marketing authorization application was rejected.
-
CLINICAL_TRIALS withdrawal · 2012-08-02Clinical Trial Update: Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST) [Phase 2]
A Phase 2 neoadjuvant trial of Tasigna (nilotinib) for gastrointestinal stromal tumor has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-05-28Clinical Trial Update: Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
A clinical trial on collection of biospecimens and clinical information from patients with gastrointestinal and gynecologic cancers was with…